Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.

 
 

Our Story

 
 
 
 

GEMoaB GmbH is a privately-owned, limited liability biopharmaceutical company based in Dresden, Germany, that is focused on becoming a leading, fully integrated biopharmaceutical company. By focusing on our proprietary next generation ATAC, UniCAR and RevCAR platforms, we intend to discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients with a high unmet medical need.

Founded in 2011 by accomplished and visionary scientists, GEMoaB rapidly grew into a highly ambitious research and development organization with unique and proprietary immunotherapy platforms and a rich pre-clinical and clinical pipeline.

We are working in close cooperation with our sister company Cellex GmbH (based in Dresden and Cologne, Germany), which is responsible for manufacturing UniCAR and RevCAR T-Cells. Cellex is a global leader in the production of allogeneic and autologous cell products. We believe that the synergy between manufacturing expertise, deep science understanding and our innovative platforms is unique and a strong foundation for our research productivity and future success.

 
 
 

 
 

Our Team

Our team is based at the BioInnovation Centre Dresden.

 
 
Team_1600x700px-03.jpg
 
Gerhard Ehninger, Prof. Dr. med.   Founding shareholder of GEMoaB and Chief Medical Officer (CMO)

Gerhard Ehninger, Prof. Dr. med.

Founding shareholder of GEMoaB and Chief Medical Officer (CMO)

Michael Bachmann, Prof. Dr. rer. nat.   Founding shareholder

Michael Bachmann, Prof. Dr. rer. nat.

Founding shareholder

Michael Pehl   Chief Executive Officer (CEO)

Michael Pehl

Chief Executive Officer (CEO)

 
Armin Ehninger, Dr. rer. nat.   Chief Scientific Officer (CSO) Protein Sciences & Immunotherapy

Armin Ehninger, Dr. rer. nat.

Chief Scientific Officer (CSO) Protein Sciences & Immunotherapy

Marc Cartellieri, Dr. rer. nat.   Chief Scientific Officer (CSO) Cellular Immunotherapy & Process Development

Marc Cartellieri, Dr. rer. nat.

Chief Scientific Officer (CSO) Cellular Immunotherapy & Process Development

Marika Geissler   Chief of Staff

Marika Geissler

Chief of Staff

 
Jana Hase   Head of Clinical Operations

Jana Hase

Head of Clinical Operations

Julia Huffziger   Head of Quality Management and Quality Assurance

Julia Huffziger

Head of Quality Management and Quality Assurance

 
 

 

Our Partners

GEMoaB is collaborating with a number of partners committed to the joint development of novel immunotherapies based on our next generation platform technologies. We are open for new clinical or strategic collaborations and also capable to generate ATACs and UniCAR/RevCAR targeting modules based on your target binding moiety of choice. Please contact us for further details.

 
 
Cellex Gesellschaft für Zellgewinnung mbH

Cellex Gesellschaft für Zellgewinnung mbH

ABX

ABX

Fraunhofer Institute for Toxicology and Experimental Medicine

Fraunhofer Institute for Toxicology and Experimental Medicine

Bio Elpida

Bio Elpida

Celgene Corporation

Celgene Corporation

Supported by:

SAB Sächsische Aufbaubank-Förderbank European Union/ European Social Fund

SAB Sächsische Aufbaubank-Förderbank
European Union/ European Social Fund

Federal Ministry of Education and Research

Federal Ministry of Education and Research

 
 
 

Download GEMoaB Company Presentation

 

News and Insights